KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) EBT Margin (2016 - 2025)

Historic EBT Margin for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to 6.52%.

  • Neogenomics' EBT Margin rose 28500.0% to 6.52% in Q4 2025 from the same period last year, while for Dec 2025 it was 15.16%, marking a year-over-year decrease of 29500.0%. This contributed to the annual value of 15.16% for FY2025, which is 29500.0% down from last year.
  • According to the latest figures from Q4 2025, Neogenomics' EBT Margin is 6.52%, which was up 28500.0% from 14.05% recorded in Q3 2025.
  • In the past 5 years, Neogenomics' EBT Margin ranged from a high of 60.33% in Q2 2021 and a low of 45.37% during Q1 2022
  • Moreover, its 5-year median value for EBT Margin was 17.92% (2023), whereas its average is 15.83%.
  • Its EBT Margin has fluctuated over the past 5 years, first surged by 809700bps in 2021, then tumbled by -931400bps in 2022.
  • Quarter analysis of 5 years shows Neogenomics' EBT Margin stood at 35.16% in 2021, then soared by 48bps to 18.4% in 2022, then skyrocketed by 47bps to 9.83% in 2023, then rose by 5bps to 9.38% in 2024, then soared by 30bps to 6.52% in 2025.
  • Its EBT Margin was 6.52% in Q4 2025, compared to 14.05% in Q3 2025 and 25.27% in Q2 2025.